After finishing at $1.79 in the prior trading day, Oncolytics Biotech Inc. (NASDAQ: ONCY) closed at $2.15, up 20.11%. In other words, the price has increased by $+0.3600 from its previous closing price. On the day, 1061233 shares were traded. ONCY stock price reached its highest trading level at $2.1500 during the session, while it also had its lowest trading level at $1.8100.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Ratios:
Our goal is to gain a better understanding of ONCY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.90 and its Current Ratio is at 13.90. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ONCY now has a Market Capitalization of 99.87M and an Enterprise Value of 76.38M.
Stock Price History:
Over the past 52 weeks, ONCY has reached a high of $2.28, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 1.3814, while the 200-Day Moving Average is calculated to be 1.4811.
Shares Statistics:
The stock has traded on average 179.84K shares per day over the past 3-months and 312.9k shares per day over the last 10 days, according to various share statistics. A total of 62.34M shares are outstanding, with a floating share count of 58.26M. Insiders hold about 1.80% of the company’s shares, while institutions hold 2.50% stake in the company. Shares short for ONCY as of Apr 27, 2023 were 68.2k with a Short Ratio of 0.07M, compared to 115.78k on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 0.11% and a Short% of Float of 0.11%.
Earnings Estimates
Its stock is currently analyzed by Oncolytics Biotech Inc. different market analysts. The consensus estimate for the next quarter is $64.28, with high estimates of $0.50 and low estimates of $0.22.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare. EPS for the following year is $Stocks, with Stocks analysts recommending between $Stocks and $Stocks.
